In older patients with unexplained hypertrophy, the default diagnosis of hypertrophic cardiomyopathy (HCM) may overlook a common culprit: transthyretin amyloid cardiomyopathy (ATTR-CM). In this AudioAbstract, Dr. Hallie Blevins explores the TTRACK study, which uncovered a striking prevalence of ATTR-CM in patients previously labeled with HCM and affirmed the real-world reliability of nuclear imaging in detecting it. Learn how imaging modalities, tracer choice, and subtle ECG or MRI findings can influence diagnostic accuracy and reshape our clinical approach.